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Abstract
Background: Safe and efficient gene transfer systems are needed for tissue engineering. We have developed an
apatite composite layer including the bone morphogenetic protein-2 (BMP-2) gene and fibronectin (FB), and we
evaluated its ability to induce bone formation.
Methods: An apatite composite layer was evaluated to determine the efficiency of gene transfer to cells cultured
on it. Cells were cultured on a composite layer including the BMP-2 gene and FB, and BMP-2 gene expression,
BMP-2 protein concentrations, alkaline phosphatase (ALP) activity, and osteocalcin (OC) concentrations were
measured. A bone defect on the cranium of rats was treated with hydroxyapatite (HAP)-coated ceramic buttons
with the apatite composite layer including the BMP-2 gene and FB (HAP-BMP-FB). The tissue concentration of BMP-
2, bone formation, and the expression levels of the BMP-2, ALP, and OC genes were all quantified.
Results: The apatite composite layer provided more efficient gene transfer for the cultured cells than an apatite
composite layer without FB. The BMP-2 concentration was approximately 100~600 pg/mL in the cell-culture
medium. Culturing the cells on the apatite composite layer for 27 days increased ALP activity and OC
concentrations. In animal experiments, the tissue concentrations of BMP-2 were over 100 pg/mg in the HAP-BMP-
FB group and approximately 50 pg/mg in the control groups. Eight weeks later, bone formation was more
enhanced in the HAP-BMP-FB group than in the control groups. In the tissues surrounding the HAP button, the
gene expression levels of ALP and OC increased.
Conclusion: The BMP-2 gene-FB-apatite composite layer might be useful for bone engineering.
Keywords: bone engineering, BMP-2 gene-fibronectin-apatite composite layer, BMP-2 gene therapy, non-viral gene
transfer.
Background
Some gene therapy systems have been reported for bone
and cartilage tissue engineering in animal models [1-9].
Bone morphogenetic protein (BMP) genes have often
been applied for bone repair, and their usefulness has
been reported in various animal experiments [1-5,8].
BMP-2 is a potent osteoinductive factor shown to
induce the osteogenic differentiation of mesenchymal
cells [10], and treatment systems using recombinant
BMP-2 protein show promise for the future. However,
these systems using recombinant proteins have several
problems, including high doses that range from
micrograms up to milligrams (which increases cost) and
the short half-life of proteins [11].
A safe and efficient gene transfer system is in high
demand in the field of tissue engineering. Gene-apatite
particles have long been used as a gene-transferring
agent [12-14]. A particulate gene-apatite composite
offers increased safety over viral and lipid-based systems,
because apatite is the main component of human hard
tissues and has both low toxicity and good biocompat-
ibility [15,16]. However, particulate gene-apatite compo-
sites have the disadvantage of inefficient gene transfer.
To improve its efficiency of gene transfer, a surface-
mediated gene transfer system derived from an apatite
composite layer was recently developed [17]. We further
improved the efficiency of gene transfer by immobilizing
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any medium, provided the original work is properly cited.cell adhesion molecules [laminin or fibronectin (FB)] in
the apatite composite layer [18-20].
Hydroxyapatite has already been applied to various
clinically approved bone substitutes to repair bone
defects. Hydroxyapatite causes minimal foreign-body
reactions and acts as an osteoconductive material by
binding to bone [21,22]. Therefore, hydroxyapatite is a
good material for use in operations, including cranio-
plasties, lamioplasties, and cervical anterior fusion. How-
ever, it has been reported that a significant amount of
time is needed for hydroxyapatite to bind to host bones
and achieve osteofusion. It would be ideal for substrates
to bind to bone quickly.
We prepared an ethylene-vinyl alcohol copolymer
(EVOH) substrate coated by an apatite composite layer
that includes both BMP-2 gene and FB (EVOH-BMP-
FB) for in vitro experiments, and we prepared hydroxya-
patite ceramic buttons (HAPs) with the apatite compo-
site layer including the BMP-2 gene and FB (HAP-
BMP-FB) for in-vivo experiments. The aim was to evalu-
ate the efficiency of gene transfer mediated by this apa-
tite composite layer and the feasibility of using this gene
transfer system in bone engineering.
Materials and methods
Cell culture
Mouse preosteoblast MC3T3-E1 cells, mouse embryonic
mesenchymal cells, C3H10T1/2 cells and human cervi-
cal cancer HeLa cells were purchased from RIKEN Bior-
esource Center (Tsukuba, Japan). MC3T3-E1 and HeLa
cells were cultured in minimum essential medium alpha
(MEMa; Gibco-BRL, Grand Island, NY, USA) medium
including 10% fetal bovine serum (FBS; Thermo Trace,
Australia), and C3H10T1/2 cells were cultured in basal
medium eagle (BME; Gibco-BRL) including 10% FBS.
Plasmid construction
The DNA sources used were pGL3 control (Promega
Co., Madison, WI, USA) and pCI-neo (Gibco-BRL).
pGL3 control includes the cDNA of luciferase. The
cDNA of human BMP-2 was inserted into the multiple
cloning site of pCI-neo by using EcoRI and NotI sites at
the linker ends, and it was named pCI-BMP. The cDNA
of BMP-2 was cloned from HeLa cells by reverse tran-
scription PCR. The cDNA was amplified using the fol-
lowing primers: forward primer, 5’-GCGGAATT
CGACTGCGGTCTCCTAAAGGTC-3’ and reverse pri-
mer, 5’- GCGGCGGCCGCTTGCTGTACTAGCGA-
CACCCAC-3’.
Preparation of substrates
In in-vitro experiments, EVOH with a thickness of 1
mm was obtained by hot-pressing ethylene-vinyl alcohol
copolymer pellets (quoted ethylene content of 32 mol%;
Kuraray Co., Ltd, Tokyo, Japan). The EVOH was cut
into 10 × 10 mm
2 square substrates using a level-con-
trolled sample cutter (SDL-200, Dumbbell Co., Ltd,
Kawagoe, Japan). The EVOH was abraded on one side
with SiC paper (average grain size = 7.6 μm, was ultra-
sonically washed with acetone and ethanol and was then
dried under vacuum for 24 h. HAP buttons were cus-
tom-made for the in-vivo experiments because it was
not easy to form EVOH into the appropriate shape for
in-vivo experiments and because HAP is a very popular
biomaterial [23]. Pure, stoichiometric hydroxyapatite
powder was supplemented with 3% (wt. %) polyvinyl
alcohol and 1% (wt. %) polyethylene glycol, sieved to
select only particles under 75 μm in size, then formed
into disks at 98 MPa and sintered at 1150°C for one
hour. The resulting shape of the HAP buttons is shown
in Figure four A, and each button has a surface area of
15.94 mm
2 and a mean thickness of 1.00 mm. The HAP
buttons were designed for a round cranial bone defect 5
mm in diameter, and their sides were cut bilaterally to
permit bone formation into the space that was created
by cutting (Figure 1A).
Deposition of amorphous calcium phosphate on the
surface of the substrate
Unlike HAP, EVOH has no nucleation site for apatite
on its surface. Therefore, a surface modification process
using amorphous calcium phosphate as a nucleating
agent for the apatite was applied to the EVOH prior to
the coating process [24-26]. EVOH was used in all of
the in-vitro experiments. The EVOH was subjected to
the following amorphous calcium phosphate-modifica-
tion process, which was originally developed for an apa-
tite coating process [27]. First, each substrate was
dipped into 20 ml of aqueous 200 mM CaCl2 (Nacalai
Tesque, Inc., Kyoto, Japan) for 10 s, then into ultrapure
water for 1 s, and then dried. Each substrate was then
dipped into 20 ml of aqueous 200 mM K2HPO4·3H2O
(Nacalai Tesque, Inc.) for 10 s, then into ultrapure
water for 1 s, and then dried. The alternate dipping into
calcium and phosphate ion solutions described above
was performed three times. As a result of this process,
nanoparticles of amorphous calcium phosphate, which is
a precursor of apatite, were deposited onto each EVOH
substrate [28].
Coating process
A calcium phosphate (CP) solution was prepared by dis-
solving NaCl (final concentration = 142 mM),
K2HPO4·3H2O (1.50 mM), 1 M HCl solution (40 mM),
and CaCl2 (3.75 mM) (Nacalai Tesque Inc.) in ultrapure
water and then buffering the solution at pH = 7.40 at
25°C with tris(hydroxymethyl)aminomethane (final con-
centration = 50 mM) and the necessary quantity of 1 M
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were prepared by supplementing CP solution with 40
μg/mL of plasmid and/or 20 μg/mL FB. The FB source
that was used was 1 mg/mL FB from bovine plasma
(Sigma-Aldrich). The plasmid that was used was propa-
gated and purified to a concentration of 0.7-1.2 mg/mL.
The EVOH was sterilized by exposure to ethylene oxide
gas and then aseptically immersed in 3 mL of the coat-
ing solution at 25°C for 24 h. The HAP was sterilized at
180°C for 6 h and immersed in 3 mL of the coating
solution at 25°C for 24 h. HAP lacking amorphous cal-
cium phosphate deposition was treated in 2 mL of the
coating solution at 25°C for 24 h. The coating for these
substrates was performed in CP solution alone or CP
solution including plasmid and/or FB. The following
materials were prepared:
￿ EVOH-CP and HAP-CP in CP solution alone.
￿ EVOH-FB in CP solution supplemented with FB.
￿ EVOH-DNA in CP solution supplemented with
pGL3 control.
￿ EVOH-DNA-FB in CP solution supplemented with
pGL3 control and FB.
￿ EVOH-BMP and HAP-BMP in CP solution supple-
mented with pCI-BMP.
￿ EVOH-BMP-FB and HAP-BMP-FB in CP solution
supplemented with pCI-BMP and FB.
The coating solution was clear and showed no appar-
ent spontaneous precipitation during the coating pro-
cess. The substrate that was removed from the coating
solution was gently washed with phosphate-buffered sal-
ine prior to the in-vitro or in-vivo experiments. The
immobilized doses of calcium, phosphate, DNA, and FB
were estimated by analyzing the residual coating solu-
tions [18-20,23].
Analysis of the surface of the samples
The surface structures of the samples were examined by
scanning electron microscopy (SEM; Model XL30, FEI
Company, Netherlands). The amounts of fibronectin
and plasmid immobilized on the samples’ surfaces were
estimated by analyzing the coating solutions by UV-vis
spectrophotometry (Model V-550, JASCO Corporation,
Japan) for any residual FB and plasmid after the coating.
A protein assay kit (Bio-Rad Laboratories Inc., USA)
was used to measure the FB concentration.
In-vitro experiments
The cells were seeded into a 24-well cell culture plate at
a concentration of 2 × 10
4 cells/well with 0.5 mL med-
ium. The cells were cultured on EVOH-CP, EVOH-
DNA, EVOH-DNA-FB, EVOH-BMP, or EVOH-BMP-FB
for 3 days or 7 days. In some samples, the cells were
washed three times with phosphate-buffered saline
(PBS) and lysed in 200 μL of cell culture lysis reagent
(Promega). After vortexing, the supernatant was
obtained by centrifuging. To evaluate the gene transfer
efficiency, luciferase activity was measured in cells cul-
tured on EVOH-DNA and EVOH-DNA-FB using a
luminometer (Gene Light 55, Microtec, Japan) and a
luciferase assay kit (Promega). Cells cultured on EVOH-
CP, EVOH-BMP and EVOH-BMP-FB were used to
detect BMP-2 gene expression.
A B
Figure 1 Three-dimensional views of a hydroxyapatite ceramic button (HAP) and the implantation of HAP samples into bone defects
(burr holes). A; HAPs were made for cranial repair (cranioplasty) in rats. Both sides of the HAP were cut in order for bone formation to extend
into the space around the bone defect. B; The panel demonstrates how bone formation was measured. Bone formation was quantified by
measuring the length of new bone extension into the inside of the bone defect and the thickness of the edges of the bone defect.
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MC3T3-E1 cells were seeded into a 24-well cell culture
plate at a concentration of 2 × 10
3 cells/well with 0.5
mL medium. The cells were cultured on EVOH, EVOH-
FB, EVOH-BMP, or EVOH-BMP-FB for 7 days or 27
days. The medium was replaced every week. In some
samples, the cells were washed three times with phos-
phate-buffered saline (PBS) and lysed with 200 μLo f
cell culture lysis reagent (Promega). After vortexing, the
supernatant was obtained by centrifuging. Some samples
were used to detect alkaline phosphatase (ALP) activity
and osteocalcin (OC) concentration.
Animal experiments
During all of the experiments (which were approved by
the Animal Care and Use Committee in The National
Institute of Advanced Industrial Science and Technol-
ogy), the animals were housed and handled in accordance
with the guidelines of the National Institutes of Health.
Seven- to eight-week-old male Wistar rats were pur-
chased (Japan Crea Co., Ltd., Japan). Under anesthesia, a
round craniotomy (5 mm in diameter) was drilled into
the right parietal bone. The rats were divided into three
treatment groups. In the HAP-CP group, the cranioplasty
was performed with HAP-CP alone. The HAP-BMP
g r o u pw a st r e a t e dw i t hH A P - B M Pw i t h o u tF B .T h e
HAP-BMP-FB group was treated with HAP-BMP-FB.
The rats were sacrificed at 2 and 8 weeks after the proce-
dures, and the skull bones with the defects or bone defect
tissues were removed. The bone samples were fixed in
10% formaldehyde in PBS for 4 days, demineralized in
10% ethylene diamine tetraacetic acid solution at 4°C for
3 days, and then embedded in paraffin and cut into 10-
μm-thick sections. The samples were cut into the center
of the skull defect (or at the nearest possible site) at a
right angle across the lengthwise axis of the HAP button
(Figure 1B). These sections were stained with hematoxy-
lin and eosin and viewed using an IX71 microscope sys-
tem equipped with DP-Controller imaging software
(Olympus, Japan). In cranial bone healing, it has been
reported that bone formation occurs at the periphery of
the bone defect [32] and on the dural membrane side
[33]. Bone formation was quantified by measuring the
length of new bone extension into the inside of the bone
defect and the thickness of the edges of the bone defect
using the IX71 microscope system (Olympus) (Figure
1B). In some rats, the gene expression levels of BMP-2,
ALP and OC and BMP-2 were evaluated in the tissues
inside of the bone defects.
BMP-2, ALP and OC gene expression
The in-vitro cell samples were washed three times with
PBS. The samples from the in-vitro cells or in-vivo tis-
sues were homogenized and centrifuged, and the
supernatant was used to extract RNA. Total RNA was
extracted from some samples with an RNA extraction
kit (QIAGEN). One microgram of total RNA was
reverse transcribed in a buffer containing 1 μl of oligo-
dT primers (2.5 μM), 250 μM deoxynucleotides, 10 U
RNasin (Promega) and 100 U Superscript II (Gibco-
BRL). This mixture was incubated for 75 min at 42°C
and for 5 min at 75°C. The gene expression levels of
BMP-2, ALP, OC and GAPDH were detected using the
following primers: forward primer 5’-GCCAGCCGAGC-
CAACAC-3’ and reverse primer 5’-AAATTAAA-
GAATCTCCGGGTTGT-3’ for human BMP2;f o r w a r d
primer 5’-GAGCAGGAACAGAAGTTTGC-3’ and
reverse primer 5’-GTTGCAGGGTCTGGAGAGTA-3’
for mouse ALP [34]; forward primer 5’-AGCTCAACCC-
CAATTGTGAC-3’ and reverse primer 5’-
AGCTGTGCCGTCCATACTTT-3’ for mouse OC [34];
and forward primer 5’-AACTCCCATTCCTCCACCTT-
3’ and reverse primer 5’-GAGGGCCTCTCTCTTG
CTCT-3’ for mouse GAPDH [34]. Each primer (12.5
pM) was added to a solution containing 12.5 μlo fi Q
SYBR green supermix (Bio-Rad Laboratories) along with
0.5 μl of template sample (final volume, 25 μl). The
Mini Opticon real-time PCR system (Bio-Rad Labora-
tories Inc.) was used. The gene expression levels were
expressed either as the delta cycle time (Δ C(t)) or the
delta-delta cycle time (Δ-Δ C(t)), and values normalized
to GAPDH expression were compared with the gene
expression in HAP-CP.
BMP-2 and OC protein concentrations and ALP activity
The cell-culture medium was used to measure the con-
centration of BMP-2 protein using the human/mouse/
rat BMP-2 Quantikine ELISA kit (R&D Technologies
Inc. RI, USA). Cells cultured on the substrate were lysed
by freezing and thawing for three cycles in 200 μlo f
PBS including 1% TritonX-100. Then, the cell lysis solu-
tion was centrifuged at 12,000 g for 2 min at 4°C. The
supernatant was used to measure ALP activity using a
LabAssay ALP activity kit (Wako Pure Chemical Indus-
tries, Ltd., Japan). Protein was quantified in the cell lysis
supernatants using a micro-BCA protein assay kit
(Thermo Fisher Scientific Inc., MA, USA). The concen-
tration of OC protein in the culture medium was mea-
sured using a rat osteocalcin enzyme immunometric
assay kit (Biomedical Technologies Inc., USA). The tis-
sues inside the bone defect were homogenized in 400 μl
of PBS including 1% Triton X-100, and then, the cell
lysate solutions were centrifuged. The supernatant was
used to measure the concentration of BMP-2 protein
using a human/mouse/rat BMP-2 Quantikine ELISA kit
(R&D Technologies Inc.). Protein was quantified in the
supernatant using a micro-BCA protein assay kit
(Thermo Fisher Scientific Inc.).
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The experimental results are expressed as the mean ±
the standard deviation. All data were analyzed using
Student’s t-test, and probability values less than 0.05
were considered to be statistically significant.
Results
Surface evaluation
SEM and UV-vis results revealed that composite layers
containing apatite had formed on EVOH and HAP trea-
ted in CP solution supplemented with plasmid and/or
FB. A plasmid/FB/apatite composite layer formed in CP
solution supplemented with 40 μg/mL plasmid and 10
μg/mL FB, a plasmid/apatite composite layer formed in
CP solution with 40 μg/mL plasmid, an FB/apatite com-
posite layer formed in CP solution with 10 μg/mL FB,
and an apatite layer formed in CP solution alone. As
s h o w ni nt h eS E Mi m a g e so fE V O Hi nF i g u r e1 ,u n i -
form layers were observed on the surfaces of all the
samples. High magnification images (lower micrographs)
show that all the layers had microflake-like architecture
(Figure 2). The calcium dose, phosphate dose, plasmid
content, and FB dose on the sample’s surface were mea-
sured (Table 1).
In-vitro evaluation of gene expression
MC3T3-E1 and C3H10T1/2 cells were cultured on
EVOH-DNA and EVOH-DNA-FB with pGL3 control
DNA for 3 days, at which time luciferase assays were
performed. In both the MC3T3-E1 and C3H10T1/2
cells, the relative luciferase units (RLUs) were a few
times higher after growth on EVOH-DNA-FB than on
EVOH-DNA (Figure 3). Next, the pGL3 control was
switched to pCI-BMP, and the cells were cultured on
each substrate for 3 days or 7 days. After 3 days, BMP-2
expression was a few fold higher in both cell lines after
growth on EVOH-BMP-FB compared with EVOH-BMP
(Figure 4A, B). After 7 days, numerous MC3T3-E1 cells
h a dd e t a c h e df r o mb o t hE V O H - B M P - F Ba n dE V O H -
BMP due to cell confluence, and BMP-2 expression
could not be evaluated (Figure 4A). Some C3H10T1/2
cells had detached and BMP-2 expression remained at
the same level as that of the 3-day samples (Figure 4B).
BMP-2 concentrations were measured in the 3 day-cul-
ture medium from both EVOH-BMP and EVOH-BMP-
FB. The BMP-2 concentration increased to over 600 pg/
mL in the C3H10T1/2 cell-cultured medium (Figure
4C). These findings suggested that the presence of FB
enhanced gene transfer in both the EVOH-BMP-FB and
EVOH-DNA-FB substrates, and gene expression maybe
sustained for one week.
In-vitro bone development
Bone induction in the MC3T3-E1 cells cultured on each
substrate was evaluated by measuring ALP activity and
OC protein levels. The MC3T3-E1 cells were cultured
for 9 and 27 days and each assay was performed. In the
cells grown on EVOH-BMP-FB, ALP activity increased
with culturing time and was significantly higher than
that in cells grown on EVOH-BMP at Day 27 (Figure
5A). OC levels were significantly higher when the cells
w e r eg r o w no nE V O H - B M P - F Bt h a no nE V O H - B M P
(Figure 5B). These findings indicate that BMP-2
expressed by gene transfer from EVOH-BMP or EVOH-
BMP-FB maintains its biological activity and induces
bone development in MC3T3-E1 cells.
In-vivo gene transfer
Bone defect rat models treated with HAP-CP, HAP-
BMP, or HAP-BMP-FB were sacrificed 2 weeks after the
procedure (n = 3 for each group). The tissues in the
bone deficit were taken, BMP-2 gene expression was
evaluated with real-time PCR using primers specific to
human BMP-2 and BMP-2 concentrations in the tissues
were assessed using the human/mouse/rat BMP-2
Quantikine ELISA kit (R&D Technologies Inc.). BMP-2
Figure 2 SEM photos of the EVOH-CP, EVOH-FB, EVOH-DNA and EVOH-DNA-FB substrates. Uniform layers were observed on the surfaces
of all the samples. High magnification images (the lower micrographs) show that all these layers have a microflake-like architecture.
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HAP-BMP-FB than in those treated with HAP-BMP or
HAP-CP (Figure 6A). The BMP-2 concentration was
approximately 108 pg/mg in HAP-BMP-FB, which was
higher than that in HAP-BMPo rH A P - C P( F i g u r e6 B ) .
These results suggest that the in-vivo gene transfer abil-
ity of HAP-BMP-FB is higher than that of HAP-BMP.
In-vivo bone development
The rat models with a bone deficit treated with HAP-
CP, HAP-BMP, or HAP-BMP-FB were sacrificed 8
weeks after the procedure (n = 5 for each group). Bone
formation was quantified by measuring the length of
new bone extension into the inside of the bone defect
and the thickness of the edges of the bone defect [23].
Small pieces of tissues in the bone defect were taken,
and the expression levels of the ALP and OC genes were
evaluated. Figure 7A shows histological sections of bone
formation at the edge of the cranium in the bone defect.
In the HAP-BMP-FB group, bone formation was
enhanced significantly more than in the HAP-BMP and
HAP-CP groups (Figure 7B). The expression levels of
the ALP and OC genes increased more in the HAP-
BMP-FB group than in the HAP-BMP or HAP-CP
groups (Figure 7C). These findings suggest that HAP-
BMP-FB enhances bone formation more than HAP-
BMP or HAP-CP.
Discussion
Non-viral gene transfer systems are easier to use and
safer than viral gene transfer systems, but it is difficult
to obtain a high gene transfer ratio [35,36]. Low gene
transfer ratios have limited the application of non-viral
gene transfer systems. Cytokines require an effective
concentration to exert their biological effects, and cyto-
kine production is a component of certain gene thera-
pies. Therefore, we have been trying to improve the
gene transfer ratio of our non-viral gene transfer sys-
tems [18-20]. Some non-viral gene transfer systems
exhibit a degree of cytotoxicity because certain of their
components (such as phospholipids) are administered
in-vivo in high amounts. The cytotoxicity of the compo-
nents of non-viral gene transfer systems must be taken
into account. The elements used in our gene transfer
system are DNA, calcium phosphate, and adhesion pro-
tein, which are thought safe. In this study, we evaluated
whether our system provides gene transfer ratios high
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Figure 3 Relative luciferase assay. Relative luciferase light units
(RLUs, normalized to the protein concentration) of extracts from
MC3T3-E1 cells (empty columns) or C3H10T1/2 cells (solid columns)
cultured on EVOH-DNA and EVOH-DNA-FB for 3 days. The values
presented are the mean ± standard deviation. (n = 3, *p < 0.05, **p
< 0.001).
Table 1 The immobilized doze of calcium, phosphate, DNA and FB
Ca
(μg/cm
2)
P
(μg/cm
2)
DNA
(μg/cm
2)
Fibronectin
(μg/cm
2)
EVOH-CP 119.7 ± 4.385 69.28 ± 2.501 - -
EVOH-FB 112.9 ± 8.051 57.57 ± 3.265 - 12.30 ± 0.295
EVOH-DNA 86.57 ± 6.841 45.03 ± 1.399 12.22 ± 0.287 -
EVOH-DNA-FB 108.2 ± 3.021 57.64 ± 3.370 14.00 ± 0.579 17.84 ± 1.332
Ca
(μg/cm
2)
P
(μg/cm
2)
DNA
(μg/cm
2)
Fibronectin
(μg/cm
2)
HAP-CP 156.4 ± 8.187 67.99 ± 4.043 - -
HAP-BMP 205.9 ± 11.87 68.21 ± 7.473 16.04 ± 0.905 -
HAP-BMP-FB 158.6 ± 13.63 42.09 ± 2.820 18.62 ± 2.701 19.60 ± 1.327
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potential for in-vivo applications.
Nie et al. reported a BMP-2 gene therapy system that
uses DNA/chitosan nanoparticles [37]. In this study, the
successful case in which bone formation was enhanced
showed serum BMP-2 levels of approximately 3.5 ng/
mL instead of approximately 1 ng/mL in the control
case. The biologically effective concentration of BMP-2
protein was reported to be over 4.3 ng/mL, and it can
act in a dose-dependent manner [38]. Our gene transfer
system achieved 108 pg/mg of BMP-2 protein in tissue,
a level roughly twice that observed with HAP-CP. Even
if successful, in non-viral gene therapy the therapeutic
protein concentration might only increase to several
times that of the control. Our BMP-2 gene-FB-apatite
composite layer might stimulate osteoblasts in-vivo.
Indeed, our experiments indicated that HAP-BMP-FB
enhanced bone formation in. In some studies using
slow-releasing BMP-2 protein systems, micrograms of
proteins were immobilized in a slow-releasing material,
which might be too much considering its biologically
effective concentration [39,40]. Indeed, ectopic bone for-
mation and bony overgrowths were induced in one such
clinical trial, which might have been due to the over-
dose. Our system induces BMP-2 protein at low concen-
trations and thus might not have the toxicity and
A B
C
Figure 4 BMP-2 gene expression levels and BMP-2 protein concentrations in in-vitro experiments. BMP2 gene expression levels in extracts
from MC3T3-E1 cells (A) or C3H10T1/2 cells (B) cultured on EVOH-CP, EVOH-BMP, or EVOH-BMP-FB for 3 or 7 days. The empty columns indicate a
3-day culture and the solid columns a 7-day culture. (C) BMP-2 concentrations in the medium from cells cultured on EVOH-CP, EVOH-BMP or
EVOH-BMP-FB for 7 days. The empty columns indicate the MC3T3-E1 cells and the solid columns the C3H10T1/2 cells. The values presented are
the mean ± standard deviation. (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001).
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such as adenovirus vector systems, can induce inflam-
mation, which influences tissue regeneration. We
thought that the low toxicity of the applied system was
an important factor for tissue engineering. Our gene
transfer system consists of phosphate, calcium, plasmid
DNA and FB, which all have low toxicity. Histological
examination revealed no inflammation and no necrosis,
indicating that our gene transfer system has good tissue
compatibility. Thus, this system has promise for in-vivo
applications and merits further evaluation.
We have researched the incorporation of functional
molecules (such as genes and proteins) into apatite
composite layers and the addition of such molecules to
A B
Figure 5 Development of MC3T3-E1 cells in in-vitro experiments. A; Alkaline phosphatase activity of cells cultured on EVOH-CP, EVOH-FB,
EVOH-BMP or EVOH-BMP-FB for 9 or 27 days. B; Osteocalcin concentration of cells cultured on EVOH-CP, EVOH-FB, EVOH-BMP or EVOH-BMP-FB
for 9 or 27 days. The empty columns indicate a 9-day culture and the solid columns a 27-day culture. The values presented are the mean ±
standard deviation. (n = 3, *p < 0.01).
A B
Figure 6 BMP-2 gene expression and BMP-2 protein concentrations in animal experiments. BMP-2 gene expression (A) and BMP-2 protein
concentrations (B) were evaluated in bone defect tissue treated with HAP-CP, HAP-BMP or HAP-BMP-FB two weeks after the procedure. The
values presented are the mean ± standard deviation (n = 3, *p < 0.05, **p < 0.01).
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The ability of incorporated FB to affect gene transfer
efficiency is described in our previous report [18-20].
Briefly, cell adhesion molecules (such as FB or laminin)
incorporated into a gene-apatite composite layer
enhance cell adhesion and cell spreading on the surface
of the layer, thereby enlarging the contact area between
the cell and the layer. Because of the tight binding
between the cell adhesion molecule ligands and the
receptors on the cell surface, a stagnant microenviron-
ment is produced at the enlarged contact area between
the cell and the layer. The resulting microenvironment
is gradually enriched with DNA molecules that are
released from the layer. As a result, highly efficient gene
transfer is accomplished at the cell adhesion molecule-
gene apatite composite layer. In this study, HAP-BMP-
FB tightly bound to cells, perhaps mostly fibroblasts, in
the surrounding tissues and transferred the BMP-2
gene. BMP-2 gene expression was detected for one week
in in-vitro experiments and for 2 weeks in in-vivo
experiments, which might indicate that our gene trans-
fer system slowly releases the DNA. However, our other
reports have shown that the expression of transferred
genes peaks from 3 days to 7 days in in-vitro experi-
ments [18-20]. It was unclear when the gene expression
peaked in the in-vivo experiments. As bone formation
was observed in the in-vivo experiments despite only a
two-fold increase in BMP-2 levels in the HAP-BMP-FB
group over the HAP-BMP or HAP-CP group, the peak
BMP-2 concentration might occur at an early stage and
its value might be higher. Additional pharmaco-dynamic
evaluations should be performed in the future. Consid-
ering that cytokines would have to be administered for
an extended period to develop tissue progenitor cells, a
slow releasing gene would be convenient in tissue engi-
neering. Induced paracrine secretion of BMP-2 protein
in the bone defect could stimulate the surrounding
osteoblasts. Our treatment system would be useful in
Figure 7 Evaluation of the animal experiments. A; Histological sections of the bone defects were stained with hematoxylin and eosin after
demineralization. The bone defects were treated with HAP-CP, HAP-BMP or HAP-BMP-FB 8 weeks ago. The yellow dotted lines show the area of
bone formation (indicated by new bone). Bone formation was observed between the cranium and the dural membrane, resulting in increased
cranial thickness. Bone formation was also observed in the bone defect space as the extension of new bone. Bars indicate 100 μm. B; Bone
formation was quantified in each group. The extension of new bone into the space left by the bone defect (open columns). The increased
thickness of the cranium due to the bone formation (solid columns). The values presented are the mean ± standard deviation. (n = 5, *p < 0.05,
**p < 0.01) C; ALP and OC gene expression in the bone defect tissue 8 weeks after the procedure. Open columns indicate ALP gene expression
and solid columns indicate OC expression. The values presented are the mean ± standard deviation (n = 5, *p < 0.05, **p < 0.01).
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Page 9 of 11bone engineering. However, longer-term experiments
using animals should be planned to further evaluate the
speed and quality of bone formation, because twenty-
four weeks might be necessary for cranial defects to
completely heal in this rat model [41].
We hope that the apatite composite layer including
plasmid and FB might be applied for cranioplasty. In the
future, the use of our treatment system in biomaterials
could facilitate bone fusion at early stages after cervical
operations.
Conclusion
The BMP-2 gene-FB-apatite composite layer was able to
enhance bone formation and may be useful for bone
engineering. Our gene transfer system might be a useful
tool for tissue engineering applications, because it has
the potential to control cell differentiation and is both
safe and highly efficient.
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